[LIVE WEBINAR] Primary Human Liver Sinusoidal Endothelial Cells (LSECs): A New Tool for Drug Discovery
Join us for a webinar on using expanded primary human liver sinusoidal endothelial cells (LSECs) in evaluating hepatotoxicity risks. LSECs are highly specialized endothelial cells lining the walls of hepatic sinusoids. Their key roles include liver regeneration, the transfer of substrates between blood and liver, and immune tolerance. Despite their substantial contribution to liver function, LSECs are often overlooked during drug discovery due to insufficient cell yields after isolation and a restricted proliferation capacity.
Using upcyte® technology LSEC lots can be expanded, and the cells can be cultured – thus providing a useful in vitro tool to complement hepatotoxicity evaluation. In January 2020, upcyte and BioIVT announced a partnership in which BioIVT is the exclusive global distributor for upcyte® LSECs and other upcyte cell products.
Attend our webinar for an engaging discussion of the following topics:
- Use of upcyte® technology in expanding hepatic cells
- Function of LSECs and possible roles in liver disease
- Hepatotoxic models using LSECs in culture